Developer docs
API playgroundTry for free, no card

Search company profiles

BioTrack Capital

Full company profile

uuid0005ald

Namestring
BioTrack Capital
Legal namestring
BioTrack Capital
Company typeenum
Private
Founded yearint
2017
Descriptiontext

BioTrack operates an entrepreneur-founded investment model with a professional team whose complementary skills span research and development, clinical operations, consulting, and investment, led by Founding Partner & CEO Kevin Chen, Founding Partner Feng Tao, and Partner Lisa Lei. Revenue is generated through conventional VC mechanics: management fees on committed/invested capital across its five funds, supplemented by carried interest on realized exits. Distribution is direct, via the team's professional network and an ecosystem of leading global biopharma, medtech, and multinational healthcare conglomerates that the firm leverages both for deal sourcing and to support portfolio companies in going overseas. The firm is recognized by top-tier global LPs including pension funds, endowments, foundations, FOFs, family offices, and strategic partners, and it communicates with the market via its website and a monthly Viewpoint newsletter. As a private firm with 1-10 reported employees, BioTrack operates with a lean internal cost structure relative to its AUM scale.

Short descriptiontext

BioTrack Capital is a Shanghai-based venture capital firm founded in 2017 that manages five funds with over USD 1.5 billion AUM, investing in and incubating early-stage biotech, medtech, AI/digital healthcare, and consumer healthcare companies, with more than 100 portfolio companies to date.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital, biotech investments, healthcare investing, early-stage funding, medtech investments
Industry2 codes
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Finance and Insurance52
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital Management
No data
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BioTrack Capital is a venture capital firm that invests in and incubates outstanding early-stage biotech, medtech, and healthcare cross-disciplinary companies (including AI and digital healthcare, and consumer healthcare). The firm manages five funds with total assets under management exceeding USD 1.5 billion and operates as both an investor and a long-term partner for entrepreneurs, providing capital, industry expertise, clinical operations support, consulting, and global expansion assistance to portfolio companies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

BioTrack Capital is a venture capital firm established in 2017 that focuses on investing in and incubating outstanding early-stage biotech, medtech, and healthcare cross-disciplinary sectors including AI and digital healthcare, and consumer healthcare. The firm manages multiple investment funds (including Fund II with approximately USD 250 million) and offers venture capital investment services as its core offering. BioTrack positions itself as both an investor and long-term partner for entrepreneurs, with a portfolio of over 100 companies including public companies and sub-sector leaders. The firm operates an ecosystem consisting of leading global biopharma, medtech companies and multinational healthcare conglomerates to provide industry insights, value-add services, and global expansion support for portfolio companies.

Product and service2 records
1BioTrack Fund II
CategoryInvestment Fund
2Venture Capital Investment Services
CategoryInvestment Service
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

China-based venture capital firm with a dedicated healthcare/biotech practice investing across therapeutics, medtech, and digital health stages. Direct peer — BioTrack co-invested with Qiming in Syneron Bio's $150M Series B, and both firms serve the same Chinese biotech entrepreneur base.

TypeDirect peer
Description

Asia-focused investment firm with a sizeable healthcare and biotech practice covering early-stage therapeutics, medtech, and healthcare services. Comparable as a Chinese healthcare investor competing for similar biotech deal flow and overlapping LP base.

TypeDirect peer
Description

Healthcare-focused venture capital firm investing in early- and growth-stage biotech, medtech, and digital health companies in China and the US. Direct peer — co-led Syneron Bio's $150M Series B alongside BioTrack, addressing the same founder pool.

4CDH Investments (CDH VGC)
TypeBroad incumbent
Description

Major China-based alternative asset manager with venture, growth, and buyout exposures including a dedicated healthcare practice. Comparable as a co-investor (Syneron Bio Series B) and as a broader incumbent whose healthcare team targets the same sectors at multiple stages.

5Yonjin Capital
TypeDirect peer
Description

Healthcare/biotech-focused venture capital firm based in China investing in innovative therapeutics and medtech. Direct peer — co-invested with BioTrack in Rapafusyn Pharmaceuticals' $44M Series A.

TypeDirect peer
Description

Chinese healthcare-specialist private equity firm investing across pharmaceuticals, biotech, medtech, and healthcare services. Comparable thesis, geography, and stage focus to BioTrack Capital.

TypeDirect peer
Description

China-focused alternative asset manager with dedicated healthcare and biotech investment programs. Comparable as a Chinese healthcare investor competing for similar founder relationships and capital pools.

TypeDirect peer
Description

Asia-based healthcare/biotech-focused venture and growth investor focused on therapeutics and medical innovations. Comparable in sector specialization and Chinese biotech deal sourcing.

TypeDirect peer
Description

China-focused healthcare/biotech investment firm with both public and private equity strategies covering therapeutics, medtech, and healthcare services. Comparable to BioTrack in geography and healthcare specialization.

10Delian Capital (德联资本)
TypeRegional player
Description

China-focused venture capital firm with healthcare/biotech among its core investment themes. Comparable Chinese-anchored healthcare specialist addressing overlapping founder and LP ecosystems.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment92 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioTrack Capital

Venture Capital Managementbiotrackcapital.com

BioTrack Capital is a Shanghai-based venture capital firm founded in 2017 that manages five funds with over USD 1.5 billion AUM, investing in and incubating early-stage biotech, medtech, AI/digital healthcare, and consumer healthcare companies, with more than 100 portfolio companies to date.

What BioTrack Capital does

BioTrack operates an entrepreneur-founded investment model with a professional team whose complementary skills span research and development, clinical operations, consulting, and investment, led by Founding Partner & CEO Kevin Chen, Founding Partner Feng Tao, and Partner Lisa Lei. Revenue is generated through conventional VC mechanics: management fees on committed/invested capital across its five funds, supplemented by carried interest on realized exits. Distribution is direct, via the team's professional network and an ecosystem of leading global biopharma, medtech, and multinational healthcare conglomerates that the firm leverages both for deal sourcing and to support portfolio companies in going overseas. The firm is recognized by top-tier global LPs including pension funds, endowments, foundations, FOFs, family offices, and strategic partners, and it communicates with the market via its website and a monthly Viewpoint newsletter. As a private firm with 1-10 reported employees, BioTrack operates with a lean internal cost structure relative to its AUM scale.

BioTrack Capital firmographics

Firmographics
Name
BioTrack Capital
Legal name
BioTrack Capital
Website
https://biotrackcapital.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
BioTrack Capital is a Shanghai-based venture capital firm founded in 2017 that manages five funds with over USD 1.5 billion AUM, investing in and incubating early-stage biotech, medtech, AI/digital healthcare, and consumer healthcare companies, with more than 100 portfolio companies to date.
Ownership category
akta.pro rank

BioTrack Capital industry classification

Industry
Product category
Venture Capital Management
NAICS
Portfolio Management and Investment Advice (523940), Finance and Insurance (52)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Venture capital
  • Biotech investments
  • Healthcare investing
  • Early-stage funding
  • Medtech investments

Where BioTrack Capital is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices1 record

Markets served

BioTrack Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Distribution channels1 record

Marketing channels2 records

BioTrack Capital product offering

Product offering

Core offering

BioTrack Capital is a venture capital firm that invests in and incubates outstanding early-stage biotech, medtech, and healthcare cross-disciplinary companies (including AI and digital healthcare, and consumer healthcare). The firm manages five funds with total assets under management exceeding USD 1.5 billion and operates as both an investor and a long-term partner for entrepreneurs, providing capital, industry expertise, clinical operations support, consulting, and global expansion assistance to portfolio companies.

Product overview

BioTrack Capital is a venture capital firm established in 2017 that focuses on investing in and incubating outstanding early-stage biotech, medtech, and healthcare cross-disciplinary sectors including AI and digital healthcare, and consumer healthcare. The firm manages multiple investment funds (including Fund II with approximately USD 250 million) and offers venture capital investment services as its core offering. BioTrack positions itself as both an investor and long-term partner for entrepreneurs, with a portfolio of over 100 companies including public companies and sub-sector leaders. The firm operates an ecosystem consisting of leading global biopharma, medtech companies and multinational healthcare conglomerates to provide industry insights, value-add services, and global expansion support for portfolio companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • BioTrack Fund II
  • Venture Capital Investment Services

Companies that use BioTrack Capital

Customer profile

Segments2 records

Ideal customer profiles2 records

BioTrack Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BioTrack Capital partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

BioTrack Capital competitors and assessment

Company assessment

Direct peers

  • Qiming Venture Partners: China-based venture capital firm with a dedicated healthcare/biotech practice investing across therapeutics, medtech, and digital health stages. Direct peer — BioTrack co-invested with Qiming in Syneron Bio's $150M Series B, and both firms serve the same Chinese biotech entrepreneur base.
  • Hillhouse Capital (HHLR): Asia-focused investment firm with a sizeable healthcare and biotech practice covering early-stage therapeutics, medtech, and healthcare services. Comparable as a Chinese healthcare investor competing for similar biotech deal flow and overlapping LP base.
  • Decheng Capital: Healthcare-focused venture capital firm investing in early- and growth-stage biotech, medtech, and digital health companies in China and the US. Direct peer — co-led Syneron Bio's $150M Series B alongside BioTrack, addressing the same founder pool.
  • Yonjin Capital: Healthcare/biotech-focused venture capital firm based in China investing in innovative therapeutics and medtech. Direct peer — co-invested with BioTrack in Rapafusyn Pharmaceuticals' $44M Series A.
  • Highlight Capital (弘晖资本): Chinese healthcare-specialist private equity firm investing across pharmaceuticals, biotech, medtech, and healthcare services. Comparable thesis, geography, and stage focus to BioTrack Capital.
  • Loyal Valley Capital (君联资本/Orchid Asia-related funds vary; using Loyal Valley proper): China-focused alternative asset manager with dedicated healthcare and biotech investment programs. Comparable as a Chinese healthcare investor competing for similar founder relationships and capital pools.
  • Apricot Capital: Asia-based healthcare/biotech-focused venture and growth investor focused on therapeutics and medical innovations. Comparable in sector specialization and Chinese biotech deal sourcing.
  • Lake Bleu Capital: China-focused healthcare/biotech investment firm with both public and private equity strategies covering therapeutics, medtech, and healthcare services. Comparable to BioTrack in geography and healthcare specialization.

Broad incumbents

  • CDH Investments (CDH VGC): Major China-based alternative asset manager with venture, growth, and buyout exposures including a dedicated healthcare practice. Comparable as a co-investor (Syneron Bio Series B) and as a broader incumbent whose healthcare team targets the same sectors at multiple stages.

Regional players

  • Delian Capital (德联资本): China-focused venture capital firm with healthcare/biotech among its core investment themes. Comparable Chinese-anchored healthcare specialist addressing overlapping founder and LP ecosystems.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

BioTrack Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioTrack Capital leadership team

Management profile

Number of profiles

Profiles5 records

BioTrack Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioTrack Capital M&A and investment

M&A and investment

M&A

Investments92 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioTrack Capital

What does BioTrack Capital do?

BioTrack Capital is a venture capital firm that invests in and incubates outstanding early-stage biotech, medtech, and healthcare cross-disciplinary companies (including AI and digital healthcare, and consumer healthcare). The firm manages five funds with total assets under management exceeding USD 1.5 billion and operates as both an investor and a long-term partner for entrepreneurs, providing capital, industry expertise, clinical operations support, consulting, and global expansion assistance to portfolio companies.

Is BioTrack Capital a public or private company?

BioTrack Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BioTrack Capital founded?

BioTrack Capital was founded in 2017. It employs 11 to 50 people.

Where is BioTrack Capital based?

BioTrack Capital is headquartered in Shanghai, China, in the Asia region.

Who are BioTrack Capital's main competitors?

Direct peers on record are Qiming Venture Partners, Hillhouse Capital (HHLR), Decheng Capital, Yonjin Capital, Highlight Capital (弘晖资本), Loyal Valley Capital (君联资本/Orchid Asia-related funds vary; using Loyal Valley proper), Apricot Capital and Lake Bleu Capital. CDH Investments (CDH VGC) is listed as a broad incumbent. Delian Capital (德联资本) is listed as a regional player.

Does BioTrack Capital have an API?

No public API is recorded for BioTrack Capital.

What industry is BioTrack Capital in?

BioTrack Capital's product category is Venture Capital Management. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireConvergen Secures $15 Million Seed+ Financing to Advance Therapeutics for Protein Aggregation DiseasesConvergen closed a $15 million Seed+ financing round led by MPCi, with participation from LAV, BioTrack Capital, and a biotech fund. The company previously raised $10 million in seed financing. Proceeds will advance its proprietary degrader platform and pipeline for neurodegenerative and protein aggregation diseases.BioSpaceConvergen Secures $15 Million Seed+ Financing to Advance Therapeutics for Protein Aggregation DiseasesConvergen closed a $15 million seed+ financing round led by MPCi, with participation from LAV, BioTrack Capital, and a biotech fund. The company previously raised $10 million in seed financing. Proceeds will advance its proprietary degrader platform and pipeline for neurodegenerative and protein aggregation diseases.MarketScreenerChinese EV battery makers pledge to pay suppliers more quicklyMajor Chinese EV battery makers CATL, CALB, and Sunwoda pledged to pay suppliers within 60 days, following an initiative by the China Automotive Battery Innovation Alliance. The move aims to ease financial strain on suppliers, who face cash shortages from long payment cycles and rising input costs.MarketScreenerShanghai Carbonology Co., Ltd. announced that it has received funding from BioTrack Capital, Gaorong Capital, Contemporary Amperex Technology Co., Limited, Efung Capital, Sungrow Power Supply Co., Ltd., Y.R. Delta Fund, and other investorsShanghai Carbonology Co., Ltd. received funding on June 12, 2026, co-led by BioTrack Capital and Gaorong Capital, with participation from CATL, Efung Capital, Sungrow, and Y.R. Delta Fund. The company issued convertible preferred shares in the transaction.Fastdata极数“碳生万物”完成A轮融资 – Fastdata极数Carbon Creates All completed a Series A financing round co-led by Yellow River Delta Investment, Gao Rong Venture Capital, and Boyuan Capital, with new shareholders including CATL, Sungrow Power Supply, and Yifeng Capital. The funds will support a thousand-ton-level DAC project in Ningxia for e-SAF production, process scaling, core technology iteration, and talent acquisition.FinSMEsBlossomHill Therapeutics Raises $84M in Series B Extension FundingBlossomHill Therapeutics raised $84M in Series B extension funding led by Janus Henderson Investors, Brahma Capital, and BioTrack Capital. The round brings total capital to $257M, to be used for its two lead clinical programs, BH-30643 and BH-30236, and further pipeline advancement.GlobeNewswireRapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its Non-Degrading Molecular Glue Drug Discovery PlatformRapafusyn Pharmaceuticals closed an over-subscribed $44 million Series A financing, adding BioTrack Capital and Yonjin Capital. The funds will advance its RapaGlue platform for non-degrading molecular glues, with a lead ENT1 inhibitor program advancing toward IND-enabling studies.Pedaily明慧医药完成1.31亿美元Pre-IPO轮融资,奥博资本领投Minghui Pharmaceutical announced the completion of a $131 million Pre-IPO financing round led by OrbiMed, with Qiming Venture Partners co-leading and participation from TF Capital, BioTrack Capital, 5Y Capital, New Day Fund, and Wider Link Enterprise Investment Limited. Representatives from OrbiMed and Qiming Venture Partners will join the company's board of directors. The funding will accelerate the advancement of the company's core clinical-stage programs, including PD-1/VEGF bispecific antibodies and their ADCs for combination therapy, as well as support the commercialization preparation of topical JAK inhibitors in China.PR NewswireMinghui Pharmaceutical Announces USD 131 Million Pre-IPO Financing to Advance Late-Stage Pipeline and Global ExpansionMinghui Pharmaceutical closed a USD 131 million pre-IPO financing led by OrbiMed and co-led by Qiming Venture Partners, with support from TF Capital and seven new investors. Proceeds will advance clinical programs, including a PD-1/VEGF bispecific antibody and ADC combinations, and support the commercial launch of its topical JAK inhibitor in China.PR NewswirePAQ Therapeutics Announces $39 Million Series B Financing and Initiates Phase 1 Trial to Advance Novel Approach Addressing KRAS-Driven Cancers with High Unmet NeedPAQ Therapeutics raised $39 million in a Series B co-led by Bayland Capital and MRL Ventures Fund. The funds will advance its lead KRAS G12D degrader PT0253, with the first patient dosed in a Phase 1 study in Q1 2025. The company will also use the capital for IND-enabling studies on its second asset.